11，Arends MJ,Morris RG,Wyllie AH.Apoptosis:The role of endonuclease.M J Pathol 1990,136:593
22，Dolzhansky A,Basch RS.Flow cytometric determination of apoptosis in heterogenous cell.J Immuno Methods 1995,180:131
33，Su LN,Little JB.Prolonged cell cycle delay in radioresistant cell lines transfected with activated ras oncogene and/or simian virus 40 T-antigen.Radiat.Res,1993,133:73
44，Lee JM,Bernstein A.p53 mutations increase resistance to ionizing radiation.Proc.Natl.A cad.Sci.USA,1993,90:5742
55，Slichenmeyer WJ,Nelson WG,Slebos RJ,Loss of a p53-associated G1 checkpoint do not decrease cell survival following DNA damage.Cancer,1993,53:4164
6[1]Watanabe Y,et al. OK-432,Clinical,PP.120,1984,Editors:Hoshino,T. ,et al,Printed in Japan
7[2]Sawai,k.et al. The 14th International Congress of Chemotherapy. Kyoto, June, 1985. Atracts: P-29-53
8[3]Uchida,A. ,et al: Int.J.Cancer,31,1,1983.OK-432,A Streptococcal Preparation as a potent Biological Response Modifier. Editors:Ishida,N.,et al.PP44,1983,Printed in Japan
5Lombardi G, Zustovich F, Nicoletto MO, et al. Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches[J]. Am J Clin Oncol,2010,33(4) :420.
6Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions: version 5.0[M].Cochrane collaboration, 2008.
8Musani A. Treatment options for malignant pleural effusion[J]. Curr Opin Pulm Med, 2009,15(4) : 380.
9Kuzdzal J, Soja J, Szlubowski A, et al.Treatment of malignant pleural effusion[J]. Pneumonol Alergol Pol, 2003, 71(3-4) : 186.
10OSTROWSKI M J.An assessment of the longterm result of controlling the reaccumulation of malignant effusions using intracavity bleomycin[J].Cancer,1986,5:721-727.
